Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.
Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.
复制标题
DOI:
10.1002/ijc.24957
复制
发表时间:
2010-06-01
影响因子:
6.4
通讯作者:
Metelitsa, Leonid S.
中科院分区:
文献类型:
--
作者:
Xiong, Guosheng;Husseiny, Mohamed I.;Song, Liping;Erdreich-Epstein, Anat;Shackleford, Gregory M.;Seeger, Robert C.;Jaeckel, Daniela;Hensel, Michael;Metelitsa, Leonid S.
关键词:
Although tumors express potentially immunogenic tumor-associated antigens (TAAs), cancer vaccines often fail because of inadequate antigen delivery and/or insufficient activation of innate immunity. The engineering of non-pathogenic bacterial vectors to deliver TAAs of choice may provide an efficient way of presenting TAAs in an immunogenic form. In this study, we used genes of Salmonella Pathogenicity Island 2 (SPI2) to construct a novel cancer vaccine, where a TAA, survivin was fused to SseF effector protein and placed under control of SsrB, the central regulator of SPI2 gene expression. This construct uses the type III secretion system (T3SS) of Salmonella and allows preferential delivery of tumor antigen into the cytosol of antigen-presenting cells for optimal immunogenicity. In a screen of a panel of attenuated strains of Salmonella we found that a double-attenuated strain of Salmonella typhimurium, MvP728 (purD/htrA) was not toxic to mice and effectively expressed and translocated survivin protein inside cytosol of murine macrophages. We also found that a ligand for CD1d-reactive Natural Killer T (NKT) cells, α-Glucuronosylceramide (GSL1) enhanced MvP728-induced IL-12 production in human DCs and that in vivo co-administration of a NKT ligand with MvP728-Llo or MvP728-survivin enhanced effector-memory CTL responses. Furthermore, combined use of MvP728-survivin with GSL1 produced anti-tumor activity in mouse models of CT26 colon carcinoma and orthotopic DBT glioblastoma. Therefore, the use of TAA delivery via SPI-2-regulated T3SS of Salmonella and NKT ligands as adjuvants may provide a foundation for new cancer vaccines.
登录
查看更多内容
影响因子:
3.3
作者:
Gentschev, Ivaylo;Spreng, Simone;Dietrich, Guido
通讯作者:
Dietrich, Guido
影响因子:
5.4
作者:
Evans, DT;Chen, LM;Johnson, PR
通讯作者:
Johnson, PR
影响因子:
45.3
作者:
Chakravarti, A;Noll, E;Loeffler, JS
通讯作者:
Loeffler, JS
影响因子:
5.5
作者:
Husseiny, Mohamed I.;Wartha, Florian;Hensel, Michael
通讯作者:
Hensel, Michael
影响因子:
2.7
作者:
Burgos, JS;Rosol, M;Laug, WE
通讯作者:
Laug, WE